免疫治疗肺癌诱发甲状腺功能异常的研究进展

张皓婷; 郑静; 傅梦姣; 周建英

doi:10.19401/j.cnki.1007-3639.2023.07.008

您当前的位置：

首页 >

文章列表页 >

免疫治疗肺癌诱发甲状腺功能异常的研究进展

综述 | 更新时间：2025-12-31

- 免疫治疗肺癌诱发甲状腺功能异常的研究进展
- Research progress on thyroid dysfunction induced by immunotherapy for lung cancer
- 中国癌症杂志 2023年33卷第7期页码：701-706
- 作者机构：
  
  1. 浙江大学医学院附属第四医院呼吸与危重症医学科，浙江大学国际健康医学研究院，浙江金华 322000
  2. 浙江大学医学院附属第一医院呼吸与危重症医学科，浙江杭州 310003
- 作者简介：
  
  [ "张皓婷（ORCID: 0000-0001-9986-712X），硕士。" ]
  周建英（ORCID: 0000-0002-8924-935X），硕士，主任医师，浙江大学附属一院呼吸与危重症医学科名誉主任。
- 基金信息：
  
  浙江省科学技术厅重点研发计划(2019C03042)
- DOI：10.19401/j.cnki.1007-3639.2023.07.008
  中图分类号： R734.2
- 收稿：2022-10-08，
  
  修回：2022-11-24，
  
  纸质出版：2023-07-30
- 稿件说明：
移动端阅览
张皓婷, 郑静, 傅梦姣, 等. 免疫治疗肺癌诱发甲状腺功能异常的研究进展[J]. 中国癌症杂志, 2023,33(7):701-706.

Haoting ZHANG, Jing ZHENG, Mengjiao FU, et al. Research progress on thyroid dysfunction induced by immunotherapy for lung cancer[J]. China Oncology, 2023, 33(7): 701-706.
张皓婷, 郑静, 傅梦姣, 等. 免疫治疗肺癌诱发甲状腺功能异常的研究进展[J]. 中国癌症杂志, 2023,33(7):701-706. DOI： 10.19401/j.cnki.1007-3639.2023.07.008.

Haoting ZHANG, Jing ZHENG, Mengjiao FU, et al. Research progress on thyroid dysfunction induced by immunotherapy for lung cancer[J]. China Oncology, 2023, 33(7): 701-706. DOI： 10.19401/j.cnki.1007-3639.2023.07.008.

摘要

免疫检查点抑制剂[主要是程序性死亡-1/程序性死亡配体-1（programmed death-1/programmed death ligand-1，PD-1/PD-L1）抑制剂]已经逐渐成为晚期肺癌最具有前景的治疗手段。但临床医师对于免疫相关不良反应仍缺乏足够认识，免疫相关甲状腺功能异常（immune-related thyroid dysfunction，irTD）作为常见的免疫相关不良反应之一，严重时可能会危及生命。本文从发病率、发病机制、预测生物标志物及治疗等方面对PD-1/PD-L1抑制剂治疗肺癌诱发的甲状腺功能异常进行探讨。

Abstract

Immune checkpoint inhibitors [mainly programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors] have emerged as the most promising therapy in lung cancer treatment. However

clinicians still lack sufficient knowledge about immune-related adverse events. Immune-related thyroid dysfunction (irTD)

one of the common immune-related adverse events

can be life-threatening in severe cases. This article discussed the thyroid dysfunction induced by PD-1/PD-L1 inhibitors in the treatment of lung cancer from the aspects of the incidence

pathogenesis

predictive biomarkers and treatment of irTD.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.v71.3 http://doi.org/10.3322/caac.v71.3 https://onlinelibrary.wiley.com/toc/15424863/71/3 https://onlinelibrary.wiley.com/toc/15424863/71/3

周彩存 , 王洁 , 王宝成 , 等 . 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2020年版) [J ] . 中国肺癌杂志 , 2021 , 24 ( 4 ): 217 - 235 .

ZHOU C C , WANG J , WANG B C , et al . Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer (2020 version) [J ] . Chin J Lung Cancer , 2021 , 24 ( 4 ): 217 - 235 .

BORGHAEI H , PAZ-ARES L , HORN L , et al . Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer [J ] . N Engl J Med , 2015 , 373 ( 17 ): 1627 - 1639 . DOI: 10.1056/NEJMoa1507643 http://doi.org/10.1056/NEJMoa1507643 http://www.nejm.org/doi/10.1056/NEJMoa1507643 http://www.nejm.org/doi/10.1056/NEJMoa1507643

BRAHMER J , RECKAMP K L , BAAS P , et al . Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer [J ] . N Engl J Med , 2015 , 373 ( 2 ): 123 - 135 . DOI: 10.1056/NEJMoa1504627 http://doi.org/10.1056/NEJMoa1504627 http://www.nejm.org/doi/10.1056/NEJMoa1504627 http://www.nejm.org/doi/10.1056/NEJMoa1504627

MOK T S K , WU Y L , KUDABA I , et al . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J ] . Lancet , 2019 , 393 ( 10183 ): 1819 - 1830 . DOI: 10.1016/S0140-6736(18)32409-7 http://doi.org/10.1016/S0140-6736(18)32409-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673618324097 https://linkinghub.elsevier.com/retrieve/pii/S0140673618324097

READY N E , OTT P A , HELLMANN M D , et al . Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort [J ] . J Thorac Oncol , 2020 , 15 ( 3 ): 426 - 435 . DOI: S1556-0864(19)33531-2 http://doi.org/S1556-0864(19)33531-2

HELLMANN M D , PAZ-ARES L , BERNABE CARO R , et al . Nivolumab plus ipilimumab in advanced non-small-cell lung cancer [J ] . N Engl J Med , 2019 , 381 ( 21 ): 2020 - 2031 . DOI: 10.1056/NEJMoa1910231 http://doi.org/10.1056/NEJMoa1910231 http://www.nejm.org/doi/10.1056/NEJMoa1910231 http://www.nejm.org/doi/10.1056/NEJMoa1910231

CARBONE D P . First-line nivolumab in stage Ⅳ or recurrent non-small cell lung cancer [J ] . Oncol Times , 2017 , 39 ( 17 ): 28 - 29 .

RECK M , RODRÍGUEZ-ABREU D , ROBINSON A G , et al . Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer [J ] . N Engl J Med , 2016 , 375 ( 19 ): 1823 - 1833 . DOI: 10.1056/NEJMoa1606774 http://doi.org/10.1056/NEJMoa1606774 http://www.nejm.org/doi/10.1056/NEJMoa1606774 http://www.nejm.org/doi/10.1056/NEJMoa1606774

WU Y L , LU S , CHENG Y , et al . Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial [J ] . J Thorac Oncol , 2019 , 14 ( 5 ): 867 - 875 . DOI: 10.1016/j.jtho.2019.01.006 http://doi.org/10.1016/j.jtho.2019.01.006 https://linkinghub.elsevier.com/retrieve/pii/S1556086419300206 https://linkinghub.elsevier.com/retrieve/pii/S1556086419300206

WU Y L , ZHANG L , FAN Y , et al . Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer: KEYNOTE-042 China study [J ] . Int J Cancer , 2021 , 148 ( 9 ): 2313 - 2320 . DOI: 10.1002/ijc.v148.9 http://doi.org/10.1002/ijc.v148.9 https://onlinelibrary.wiley.com/toc/10970215/148/9 https://onlinelibrary.wiley.com/toc/10970215/148/9

ANTONIA S J , VILLEGAS A , DANIEL D , et al . Durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer [J ] . N Engl J Med , 2017 , 377 ( 20 ): 1919 - 1929 . DOI: 10.1056/NEJMoa1709937 http://doi.org/10.1056/NEJMoa1709937 http://www.nejm.org/doi/10.1056/NEJMoa1709937 http://www.nejm.org/doi/10.1056/NEJMoa1709937

BARLESI F , VANSTEENKISTE J , SPIGEL D , et al . Avelumab versus docetaxel in patients with platinum-treated advanced non-small cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study [J ] . Lancet Oncol , 2018 , 19 ( 11 ): 1468 - 1479 . DOI: 10.1016/S1470-2045(18)30673-9 http://doi.org/10.1016/S1470-2045(18)30673-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204518306739 https://linkinghub.elsevier.com/retrieve/pii/S1470204518306739

GANDHI L , RODRÍGUEZ-ABREU D , GADGEEL S , et al . Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer [J ] . N Engl J Med , 2018 , 378 ( 22 ): 2078 - 2092 . DOI: 10.1056/NEJMoa1801005 http://doi.org/10.1056/NEJMoa1801005 http://www.nejm.org/doi/10.1056/NEJMoa1801005 http://www.nejm.org/doi/10.1056/NEJMoa1801005

NISHIO M , BARLESI F , WEST H , et al . Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial [J ] . J Thorac Oncol , 2021 , 16 ( 4 ): 653 - 664 . DOI: 10.1016/j.jtho.2020.11.025 http://doi.org/10.1016/j.jtho.2020.11.025 https://linkinghub.elsevier.com/retrieve/pii/S155608642031100X https://linkinghub.elsevier.com/retrieve/pii/S155608642031100X

PAZ-ARES L , DVORKIN M , CHEN Y B , et al . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J ] . Lancet , 2019 , 394 ( 10212 ): 1929 - 1939 . DOI: 10.1016/S0140-6736(19)32222-6 http://doi.org/10.1016/S0140-6736(19)32222-6 https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226 https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226

PAZ-ARES L , LUFT A , VICENTE D , et al . Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer [J ] . N Engl J Med , 2018 , 379 ( 21 ): 2040 - 2051 . DOI: 10.1056/NEJMoa1810865 http://doi.org/10.1056/NEJMoa1810865 http://www.nejm.org/doi/10.1056/NEJMoa1810865 http://www.nejm.org/doi/10.1056/NEJMoa1810865

WEST H , MCCLEOD M , HUSSEIN M , et al . Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2019 , 20 ( 7 ): 924 - 937 . DOI: 10.1016/S1470-2045(19)30167-6 http://doi.org/10.1016/S1470-2045(19)30167-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204519301676 https://linkinghub.elsevier.com/retrieve/pii/S1470204519301676

BOYER M , ŞENDUR M A N , RODRÍGUEZ-ABREU D , et al . Pembrolizumab plus ipilimumab or placebo for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50%: randomized, double-blind phase Ⅲ KEYNOTE-598 study [J ] . J Clin Oncol , 2021 , 39 ( 21 ): 2327 - 2338 . DOI: 10.1200/JCO.20.03579 http://doi.org/10.1200/JCO.20.03579 https://ascopubs.org/doi/10.1200/JCO.20.03579 https://ascopubs.org/doi/10.1200/JCO.20.03579

HORN L , MANSFIELD A S , SZCZĘSNA A , et al . First-line atezolizumab plus chemotherapy in extensive-stage small cell lung cancer [J ] . N Engl J Med , 2018 , 379 ( 23 ): 2220 - 2229 . DOI: 10.1056/NEJMoa1809064 http://doi.org/10.1056/NEJMoa1809064 http://www.nejm.org/doi/10.1056/NEJMoa1809064 http://www.nejm.org/doi/10.1056/NEJMoa1809064

PROF , LUIS , PAZ-ARES , et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 2 ): 198 - 211 . DOI: 10.1016/S1470-2045(20)30641-0 http://doi.org/10.1016/S1470-2045(20)30641-0 https://linkinghub.elsevier.com/retrieve/pii/S1470204520306410 https://linkinghub.elsevier.com/retrieve/pii/S1470204520306410

National Cancer Institute . Protocol development cancer therapy evaluation program [EB/OL ] . ( 2017-11-27 )[ 2023-04-28 ] . https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.

KHAN U , RIZVI H , SANO D , et al . Nivolumab induced myxedema crisis [J ] . J Immunother Cancer , 2017 , 5 : 13 . DOI: 10.1186/s40425-017-0213-x http://doi.org/10.1186/s40425-017-0213-x

ZHOU N , VELEZ M A , BACHRACH B , et al . Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC [J ] . Lung Cancer , 2021 , 161 : 34 - 41 . DOI: 10.1016/j.lungcan.2021.08.009 http://doi.org/10.1016/j.lungcan.2021.08.009

YAMAZAKI H , IWASAKI H , YAMASHITA T , et al . Potential risk factors for nivolumab-induced thyroid dysfunction [J ] . In Vivo , 2017 , 31 ( 6 ): 1225 - 1228 .

OSORIO J C , NI A , CHAFT J E , et al . Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small cell lung cancer [J ] . Ann Oncol , 2017 , 28 ( 3 ): 583 - 589 . DOI: 10.1093/annonc/mdw640 http://doi.org/10.1093/annonc/mdw640 https://linkinghub.elsevier.com/retrieve/pii/S0923753419319593 https://linkinghub.elsevier.com/retrieve/pii/S0923753419319593

KOTWAL A , GUSTAFSON M P , BORNSCHLEGL S , et al . Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations [J ] . Thyroid , 2020 , 30 ( 10 ): 1440 - 1450 . DOI: 10.1089/thy.2020.0075 http://doi.org/10.1089/thy.2020.0075 https://www.liebertpub.com/doi/10.1089/thy.2020.0075 https://www.liebertpub.com/doi/10.1089/thy.2020.0075

TORIMOTO K , OKADA Y , NAKAYAMADA S , et al . Anti-PD-1 antibody therapy induces Hashimoto’s disease with an increase in peripheral blood follicular helper T cells [J ] . Thyroid , 2017 , 27 ( 10 ): 1335 - 1336 . DOI: 10.1089/thy.2017.0062 http://doi.org/10.1089/thy.2017.0062 https://www.liebertpub.com/doi/10.1089/thy.2017.0062 https://www.liebertpub.com/doi/10.1089/thy.2017.0062

KIMBARA S , FUJIWARA Y , IWAMA S , et al . Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab [J ] . Cancer Sci , 2018 , 109 ( 11 ): 3583 - 3590 . DOI: 10.1111/cas.2018.109.issue-11 http://doi.org/10.1111/cas.2018.109.issue-11 https://onlinelibrary.wiley.com/toc/13497006/109/11 https://onlinelibrary.wiley.com/toc/13497006/109/11

YAMAUCHI I , YASODA A , MATSUMOTO S , et al . Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab [J ] . PLoS One , 2019 , 14 ( 5 ): e0216954 . DOI: 10.1371/journal.pone.0216954 http://doi.org/10.1371/journal.pone.0216954 https://dx.plos.org/10.1371/journal.pone.0216954 https://dx.plos.org/10.1371/journal.pone.0216954

SABINI E , SFRAMELI A , MARINÒ M . A case of drug-induced Graves’ orbitopathy after combination therapy with tremelimumab and durvalumab [J ] . J Endocrinol Invest , 2018 , 41 ( 7 ): 877 - 878 . DOI: 10.1007/s40618-018-0906-0 http://doi.org/10.1007/s40618-018-0906-0

ZHAN L , FENG H F , LIU H Q , et al . Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management [J ] . Front Endocrinol (Lausanne) , 2021 , 12 : 649863 . DOI: 10.3389/fendo.2021.649863 http://doi.org/10.3389/fendo.2021.649863 https://www.frontiersin.org/articles/10.3389/fendo.2021.649863/full https://www.frontiersin.org/articles/10.3389/fendo.2021.649863/full

MAZARICO I , CAPEL I , GIMÉNEZ-PALOP O , et al . Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors [J ] . J Endocrinol Invest , 2019 , 42 ( 12 ): 1443 - 1450 . DOI: 10.1007/s40618-019-01058-x http://doi.org/10.1007/s40618-019-01058-x

YAMAUCHI I , SAKANE Y , FUKUDA Y , et al . Clinical features of nivolumab-induced thyroiditis: a case series study [J ] . Thyroid , 2017 , 27 ( 7 ): 894 - 901 . DOI: 10.1089/thy.2016.0562 http://doi.org/10.1089/thy.2016.0562

DELIVANIS D A , GUSTAFSON M P , BORNSCHLEGL S , et al . Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms [J ] . J Clin Endocrinol Metab , 2017 , 102 ( 8 ): 2770 - 2780 . DOI: 10.1210/jc.2017-00448 http://doi.org/10.1210/jc.2017-00448

KURIMOTO C , INABA H , ARIYASU H , et al . Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors [J ] . Cancer Sci , 2020 , 111 ( 5 ): 1468 - 1477 . DOI: 10.1111/cas.v111.5 http://doi.org/10.1111/cas.v111.5 https://onlinelibrary.wiley.com/toc/13497006/111/5 https://onlinelibrary.wiley.com/toc/13497006/111/5

KRIEG C , NOWICKA M , GUGLIETTA S , et al . High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy [J ] . Nat Med , 2018 , 24 ( 2 ): 144 - 153 . DOI: 10.1038/nm.4466 http://doi.org/10.1038/nm.4466

MAEKURA T , NAITO M , TAHARA M , et al . Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer [J ] . In Vivo , 2017 , 31 ( 5 ): 1035 - 1039 .

YOON J H , HONG A R , KIM H K , et al . Characteristics of immune-related thyroid adverse events in patients treated with PD-1/PD-L1 inhibitors [J ] . Endocrinol Metab (Seoul) , 2021 , 36 ( 2 ): 413 - 423 . DOI: 10.3803/EnM.2020.906 http://doi.org/10.3803/EnM.2020.906

DE FILETTE J , ANDREESCU C E , COOLS F , et al . A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors [J ] . Horm Metab , 2019 , 51 ( 3 ): 145 - 156 .

KOTWAL A , KOTTSCHADE L , RYDER M . PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients [J ] . Thyroid , 2020 , 30 ( 2 ): 177 - 184 . DOI: 10.1089/thy.2019.0250 http://doi.org/10.1089/thy.2019.0250

CAMPREDON P , MOULY C , LUSQUE A , et al . Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients [J ] . Presse Med , 2019 , 48 ( 4 ): e199 - e207 . DOI: 10.1016/j.lpm.2018.10.019 http://doi.org/10.1016/j.lpm.2018.10.019 https://linkinghub.elsevier.com/retrieve/pii/S0755498219300880 https://linkinghub.elsevier.com/retrieve/pii/S0755498219300880

POLLACK R , ASHASH A , CAHN A , et al . Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index [J ] . J Clin Endocrinol Metab , 2020 , 105 ( 10 ): dgaa458 .

D'AIELLO A , LIN J , GUCALP R , et al . Thyroid dysfunction in lung cancer patients treated with immune checkpoint inhibitors (ICIs): outcomes in a multiethnic urban cohort [J ] . Cancers (Basel) , 2021 , 13 ( 6 ): 1464 . DOI: 10.3390/cancers13061464 http://doi.org/10.3390/cancers13061464 https://www.mdpi.com/2072-6694/13/6/1464 https://www.mdpi.com/2072-6694/13/6/1464

彭智 , 袁家佳 , 王正航 , 等 . ASCO/NCCN免疫治疗毒性管理指南解读 [J ] . 肿瘤综合治疗电子杂志 , 2018 , 4 ( 2 ): 38 - 47 .

PENG Z , YUAN J J , WANG Z H , et al . Comments on ASCO/NCCN management guidelines of toxicities from immunotherapy [J ] . J Multidiscip Cancer Manag Electron Version , 2018 , 4 ( 2 ): 38 - 47 .

浏览量

1349

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

免疫相关不良事件中糖皮质激素及免疫抑制剂管理策略对患者生存结局的影响：系统评价与Meta分析

抗EGFR单抗联合免疫检查点抑制剂治疗头颈部鳞状细胞癌专家共识（2025年版）

免疫检查点抑制剂治疗相关胸腔积液的研究进展

复发/转移性头颈部鳞癌免疫检查点抑制剂治疗专家共识（2024年版）

托法替布治疗激素抵抗型免疫检查点抑制剂相关心肌炎的临床研究